ClinicalTrials.gg
RecruitingNCT07037862ELEVATE-44Updated Aug 13, 2026

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

A Phase 1/2 interventional study of ENTR-601-44 and ENTR-601-44 - matching placebo in Duchenne Muscular Dystrophy (DMD), sponsored by Entrada Therapeutics, Inc.. Recruiting at 14 sites in 4 countries. Open to male participants aged 4 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Entrada Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
4 Years to 20 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom — 16 open to participants now, 26 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United Kingdom.

Planned enrollment
56th of 73
24 · median 74
Started
2025
with 5 others
Phase 1/2
11 of 85
3 open now
Primary completion
2029-03
later than 14 of 25 live
Registered
77th of 85
by date
Lead sponsor
3 of 85
Entrada Therapeutics, Inc.

Among the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, this one is the 56th largest by planned enrollment of the 73 interventional ones that give a count, is one of 6 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 14 of the 25 other live ones, and was the 77th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

16 of the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 20 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.

The researchers want to: Test how safe ENTR-601-44 is, learn about any side effects, and look at the potential positive effects of ENTR-601-44, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-44 and placebo are both called study treatments.

The study has 2 parts:

  • Part A

    • A Double-Blind Period, to evaluate if ENTR-601-44 is safe and to determine the best dose of ENTR-601-44 for Part B.
    • Following the Double-Blind period, participants will roll into an open-label treatment period during which the safety and efficacy of extended dosing will be evaluated.
  • Part B

    • To further evaluate the effect and safety of ENTR-601-44 at the dose determined in Part A.

Participants will:

  • Receive study treatment in the form of multiple intravenous (IV) infusions (slow injection) into a vein over the course of several weeks in Part A and in Part B
  • Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and exercise tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a result of the study drug.

Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • Duchenne Muscular Dystrophy
  • DMD
  • exon skipping therapy
  • oligonucleotide therapy
04

Who can participate

Ages eligible
4 Years to 20 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Principal inclusion criteria

  1. Genetic diagnosis of Duchenne muscular dystrophy (DMD) and confirmed pathologic variant in the dystrophin gene amenable to exon 44 skipping as reviewed by a central genetic counselor.
  2. Assigned male at birth with clinical signs compatible with Duchenne muscular dystrophy as determined by the investigator.
  3. Part A: 4-20 years of age, inclusive.
  4. Ambulatory Status Part A: ambulatory with a Performance of the Upper Limb v2.0 (PUL 2.0) Entry as per protocol at Screening
  5. Adequate muscle for obtaining tissue as assessed by the investigator.
  6. Other protocol-defined criteria apply.

Principal exclusion criteria

  1. Any significant concomitant medical condition that might interfere with the ability to comply with protocol requirements.
  2. Has an acute illness within 4 weeks prior to the first dose of study drug which may interfere with study measurements or jeopardize participant's safety.
  3. Use of the following medications:

    1. Prior treatment with any exon skipping therapy at any time
    2. Prior treatment with any gene therapy at any time
    3. Use of anti-coagulants, anti-thrombotics, or anti- agents
    4. Use of an (other than oral for DMD conditions)
    5. Has taken or is currently taking a histone deacetylase (HDAC) inhibitor, including (but not limited to) givinostat
  4. Laboratory abnormalities.
  5. Daytime ventilator dependence or any use of invasive mechanical ventilation via tracheostomy.
  6. Has an abnormal (ECG) reading assessed as by the investigator, and/or a with Fridericia correction method (QTcF) >450 msec at Screening or prior to the first dose of study drug on Day 1.
  7. Received any experimental or drug, etc. within 3 months prior to first dose or within 5 half-lives (whichever is longer).
  8. Other protocol-defined criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    ENTR-601-44

    intravenous infusion every 6 weeks

    Drug: ENTR-601-44

  • Placebo comparator
    Placebo

    intravenous infusion every 6 weeks

    Drug: ENTR-601-44 - matching placebo

Interventions

  • DrugENTR-601-44

    intravenous infusion

  • DrugENTR-601-44 - matching placebo

    intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period)

    Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.

    Time frame: From baseline through End of Study (up to 62 weeks).

Secondary outcomes

  1. Plasma, muscle, and urine concentration of ENTR-601-44 and its final metabolite (Part A and Open Label (OL) Period)

    Time frame: From Baseline through End of Study (up to 62 weeks).

  2. Change from baseline to End of Part A in dystrophin by Western blot from muscle biopsy (Part A)

    Time frame: Baseline, End of Part A (up to 25 weeks)

  3. Change from baseline to End of Part A in dystrophin expression and localization from muscle biopsy (Part A)

    Time frame: Baseline, End of Part A (up to 25 weeks)

  4. Percent change from baseline to End of Part A in exon 44 skipping measured in muscle biopsy at End of Study (Part A)

    Time frame: Baseline, End of Part A (up to 25 weeks)

  5. Anti-drug antibody (ADA) and anti-dystrophin antibody in serum (Part A and OL Period)

    Time frame: From baseline through End of Study (up to 62 weeks).

  6. Change from baseline to End of OL Period in 10-Meter Walk/Run (10MWR) (Part A and OL Period)

    Time frame: Baseline, End of Study (up to 62 weeks)

  7. Change from baseline to End of OL Period in Timed Rise from Floor (Part A and OL Period)

    Time frame: Baseline, End of Study (up to 62 weeks)

  8. Change from baseline to End of OL Period in Timed 4-Stair Climb (4SC) (Part A and OL Period)

    Time frame: Baseline, End of Study (up to 62 weeks).

  9. Change from baseline to End of OL Period in 95th centile Stride Velocity (SV95C) (Part A and OL Period)

    Time frame: Baseline, End of Study (up to 62 weeks)

  10. Change from baseline to End of OL Period in North Star Ambulatory Assessment (NSAA) (Part A and OL Period)

    Ordinal scale with 0 as the minimum score and 34 as the maximum score (higher score - better outcome).

    Time frame: Baseline, End of Study (up to 62 weeks)

  11. Change from baseline to End of OL Period in Performance of the Upper Limb v2.0 (PUL 2.0) (Part A and OL Period)

    Ordinal scale with 0 as the minimum score and 42 as the maximum score (higher score - better outcome).

    Time frame: Baseline, End of Study (up to 62 weeks)

07

Study locations

13 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The datasets generated during and/or analysed during the current study are not expected to be made available due to due to the data's high commercial sensitivity.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2029, 44 months after the start.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2025
First posted
Jun 26, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Mar 28, 2029
CompletionEst.
Mar 28, 2029
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07037862
Lead sponsor
Entrada Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Jun 30, 2025
Primary completion
Mar 28, 2029 (estimated)
Completion
Mar 28, 2029 (estimated)
Last update
Aug 13, 2026

Study contacts

Entrada Therapeutics Clinical Trials
study director · Entrada Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion